Soon after the initial introduction of infliximab in the late 1990s, physicians and researchers noticed that for patients with inflammatory bowel disease (IBD) who responded to therapy, a significant portion would experience loss of response over time. As a result, intensifying the dose of infliximab was found to be useful in maintaining remission. In fact, … Continue reading The Need for Dose Escalation in IBD: Another Cost-Savings Advantage for Biosimilars?